Advances in Clinical Cardiology 2025: A Summary of Key Clinical Trials

INTRODUCTION: Over the course of 2025, numerous key clinical trials in the field of cardiology were published or presented at major international conferences. This review seeks to collate and summarise these trials and reflect on their clinical context. With the rapid advancements in the management of cardiovascular diseases, it is critical to evaluate the emerging evidence that may influence clinical practice and impact the development of future guidelines. METHODS: The authors evaluated all clinical trials presented at major cardiology conferences during 2025, with a focus on those likely to influence or change current clinical practice. We reviewed clinical trials presented at all major international cardiology conferences, including the American College of Cardiology (ACC), European Association for Percutaneous Cardiovascular Interventions (EuroPCR), European Society of Cardiology (ESC), Transcatheter Cardiovascular Therapeutics (TCT), American Heart Association (AHA) and the European Heart Rhythm Association (EHRA) among others. Trials considered to have the highest impact and broad relevance across the field of clinical cardiology, with a strong likelihood to change or impact clinical practice, were included. RESULTS: Over 80 key cardiology clinical trials were identified across the spectrum of clinical cardiology in 2025. Important updates in percutaneous coronary intervention were reviewed, including advances in antiplatelet strategies challenging the traditional one-year paradigm of dual antiplatelet therapy (TARGET FIRST, MASTER DAPT), alongside key developments in percutaneous coronary intervention (PCI) and drug-coated balloon (DCB) technologies (SELUTION DeNovo, AGENT IDE). Structural heart disease trials included important updates in transcatheter valve intervention and related therapies (DAPA-TAVI, FAITAVI, BHF PROTECT-TAVI), as well as key data in left atrial appendage closure (CLOSURE-AF). Major advances were also reported in heart failure and cardiomyopathy (SUMMIT, MAPLE-HCM, DIGIT-HF), together with important preventive cardiology outcomes data (VESALIUS-CV). CONCLUSION: This review offers a concise synthesis of the key clinical cardiology trials published or presented over the past year, with relevance for both clinicians and cardiovascular researchers.